

# Stan Jordan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2613196/publications.pdf>

Version: 2024-02-01

318  
papers

15,228  
citations

18436

62  
h-index

24179

110  
g-index

330  
all docs

330  
docs citations

330  
times ranked

9598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obinutuzumab for Desensitization: An Unexpected Benefit?. <i>Transplantation</i> , 2022, 106, 245-247.	0.5	1
2	Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 691-697.	2.6	26
3	Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients. <i>Transplantation</i> , 2022, 106, e90-e91.	0.5	3
4	Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. <i>Kidney International Reports</i> , 2022, 7, 720-731.	0.4	23
5	Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection. <i>Pediatric Transplantation</i> , 2022, 26, e14258.	0.5	9
6	Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. <i>Transplant Infectious Disease</i> , 2022, 24, e13813.	0.7	12
7	Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	1
8	HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates. <i>Transplantation Direct</i> , 2022, 8, e1312.	0.8	2
9	Donor-derived cell-free DNA in kidney transplantation: evolving concepts and potential limitations. <i>Kidney International</i> , 2022, 101, 676-677.	2.6	2
10	Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1133-1144.	2.6	18
11	US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response. <i>Clinical Infectious Diseases</i> , 2022, 75, 1940-1949.	2.9	3
12	Intravenous immunoglobulin contains high-titer neutralizing IgG antibodies to SARS-CoV-2. <i>American Journal of Transplantation</i> , 2022, 22, 2484-2485.	2.6	5
13	Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	7
14	Diminished T-cell Immune Responses to SARS-CoV-2 Omicron Variant after BNT162b2 Vaccination. <i>Immunology Letters</i> , 2022, , .	1.1	0
15	Reply to Olivera and Mallat. <i>Clinical Infectious Diseases</i> , 2021, 73, e272-e273.	2.9	0
16	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
17	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. <i>Transplantation</i> , 2021, 105, 436-442.	0.5	3
18	Donor-derived cell-free DNA (ddcfDNA) for detection of allograft rejection in pediatric kidney transplants. <i>Pediatric Transplantation</i> , 2021, 25, e13850.	0.5	22

#	ARTICLE	IF	CITATIONS
19	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	3.0	40
20	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1612-1621.	2.6	11
21	Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2021, 8, 127-139.	0.9	31
22	Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. <i>Clinical and Experimental Immunology</i> , 2021, 204, 310-320.	1.1	62
23	Imlifidase as a Potential Treatment for Antibody-Mediated Rejection. <i>Current Transplantation Reports</i> , 2021, 8, 157-161.	0.9	0
24	Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study. <i>International Journal of Infectious Diseases</i> , 2021, 105, 245-251.	1.5	13
25	Rationalizing Incompatible Living Donor Kidney Transplantation for Highly Sensitized Candidates. <i>Current Transplantation Reports</i> , 2021, 8, 250.	0.9	0
26	Association between ddâ€fDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort. <i>Clinical Transplantation</i> , 2021, 35, e14402.	0.8	5
27	Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 1818-1824.	0.5	14
28	Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes). <i>Transplantation</i> , 2021, 105, 1808-1817.	0.5	54
29	Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. <i>American Journal of Transplantation</i> , 2021, 21, 3907-3918.	2.6	43
30	Development of CMVâ€specific cytotoxic T cells (CMVâ€Tc) in pediatric renal transplant recipients with CMV viremia. <i>Pediatric Transplantation</i> , 2021, 25, e14119.	0.5	1
31	Use of Rituximab for persistent EBV DNAemia, and its effect on donorâ€specific antibody development in pediatric renal transplant recipients: A case series. <i>Pediatric Transplantation</i> , 2021, 25, e14113.	0.5	5
32	T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2554-2556.	4.8	72
33	Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy. <i>Translational Research</i> , 2021, 235, 48-61.	2.2	7
34	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	5.9	25
35	Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests. <i>Transplantation</i> , 2021, 105, e272-e273.	0.5	2
36	Approach to Highly Sensitized Kidney Transplant Candidates and a Positive Crossmatch. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 587-595.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 109-116.	2.2	42
38	Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection. <i>Transplantation</i> , 2020, 104, 856-863.	0.5	56
39	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	0.5	172
40	Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics. <i>Transplantation</i> , 2020, 104, 17-23.	0.5	12
41	Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients. <i>Transplantation</i> , 2020, 104, 1500-1507.	0.5	14
42	Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. <i>Transplantation</i> , 2020, 104, 1574-1579.	0.5	26
43	Interleukin-6: An Important Mediator of Allograft Injury. <i>Transplantation</i> , 2020, 104, 2497-2506.	0.5	41
44	Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 1515-1518.	0.4	37
45	Tocilizumab for Covid-19 – The Ongoing Search for Effective Therapies. <i>New England Journal of Medicine</i> , 2020, 383, 2387-2388.	13.9	36
46	The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 42-56.	2.6	27
47	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2711-2714.	0.3	33
48	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. <i>Clinical Infectious Diseases</i> , 2020, 71, 3168-3173.	2.9	73
49	Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. <i>American Journal of Transplantation</i> , 2020, 20, 2581-2588.	2.6	20
50	CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). <i>Transplantation</i> , 2020, 104, S67-S68.	0.5	3
51	Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. <i>Transplantation Direct</i> , 2020, 6, e580.	0.8	12
52	Evolving Approaches to Treatment of Allosensitization and Antibody-Mediated Rejection. , 2020, , 177-189.		0
53	THE USE OF DD-CFDNA AS A PREDICTIVE TOOL FOR FUTURE PROTEINURIA. <i>Transplantation</i> , 2020, 104, S130-S130.	0.5	0
54	Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. <i>American Journal of Transplantation</i> , 2019, 19, 381-390.	2.6	25

#	ARTICLE	IF	CITATIONS
55	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. <i>American Journal of Transplantation</i> , 2019, 19, 3035-3045.	2.6	44
56	Clinical and Public Policy Implications of Pre-Formed DSA and Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 972-974.	2.2	1
57	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. <i>Clinical Transplantation</i> , 2019, 33, e13751.	0.8	48
58	Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients. <i>Journal of the American Heart Association</i> , 2019, 8, e010570.	1.6	33
59	Allocation of the Highest Quality Kidneys and Transplant Outcomes Under the New Kidney Allocation System. <i>American Journal of Kidney Diseases</i> , 2019, 73, 605-614.	2.1	24
60	Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 1663-1670.	2.6	124
61	Immune response to non-HLA antigens and renal allograft loss. <i>Lancet, The</i> , 2019, 393, 854-856.	6.3	5
62	Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 2666-2674.	0.5	19
63	Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection. <i>Transplantation</i> , 2019, 103, 262-272.	0.5	28
64	Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation. <i>Transplantation</i> , 2019, 103, 1763-1775.	0.5	32
65	A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 2955-2964.	2.6	70
66	Immunoglobulin Gâ€“Degrading Enzyme of <i>Streptococcus pyogenes</i> (IdeS), Desensitization, and the Kidney Allocation System. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 799-801.	2.2	7
67	Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study. <i>American Journal of Transplantation</i> , 2018, 18, 650-658.	2.6	11
68	Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2018, 4, e379.	0.8	84
69	Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Failure in a Liver Transplant Patient: A Case Report. <i>Transplantation Proceedings</i> , 2018, 50, 4038-4041.	0.3	9
70	Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. <i>Kidney International</i> , 2017, 91, 729-737.	2.6	77
71	Assessment of Tocilizumab (Antiâ€“Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2381-2389.	2.6	278
72	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	3.0	365

#	ARTICLE	IF	CITATIONS
73	Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection. Transplantation, 2017, 101, 32-44.	0.5	215
74	The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis. American Journal of Transplantation, 2017, 17, 3123-3130.	2.6	25
75	Tocilizumab (Anti-IL-6R) Suppressed TNF $\alpha$ Production by Human Monocytes in an In Vitro Model of Anti-HLA Antibody-Induced Antibody-Dependent Cellular Cytotoxicity. Transplantation Direct, 2017, 3, e139.	0.8	11
76	Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients. Transplantation, 2017, 101, 883-889.	0.5	25
77	Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology, 2017, 139, S1-S46.	1.5	454
78	Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization. Transplant Immunology, 2017, 45, 59-64.	0.6	5
79	Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients. Pediatric Transplantation, 2017, 21, e13042.	0.5	4
80	Outcomes of Highly Sensitized Patients Undergoing Simultaneous Liver and Kidney Transplantation: A Single-Center Experience With Desensitization. Transplantation Proceedings, 2017, 49, 1394-1401.	0.3	4
81	IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. New England Journal of Medicine, 2017, 377, 442-453.	13.9	257
82	Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies. Pediatric Transplantation, 2017, 21, e13079.	0.5	6
83	Desensitization: Overcoming the Immunologic Barriers to Transplantation. Journal of Immunology Research, 2017, 2017, 1-11.	0.9	67
84	Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. Journal of Immunology Research, 2017, 2017, 1-24.	0.9	28
85	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. Journal of Applied Laboratory Medicine, 2017, 2, 309-321.	0.6	59
86	Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Transplantation, 2017, 101, 2419-2428.	0.5	47
87	Liver Transplantation in a Patient With CD40 Ligand Deficiency and Hyper-IgM Syndrome: Clinical and Immunological Assessments. American Journal of Transplantation, 2016, 16, 1626-1632.	2.6	9
88	Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients. Transplantation Proceedings, 2016, 48, 806-808.	0.3	12
89	Progress in Desensitization of the Highly HLA Sensitized Patient. Transplantation Proceedings, 2016, 48, 802-805.	0.3	9
90	Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transplant Immunology, 2016, 38, 84-92.	0.6	29

#	ARTICLE	IF	CITATIONS
91	Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. <i>Transplant International</i> , 2016, 29, 1276-1285.	0.8	38
92	Novel role of Vav1-Rac1 pathway in actin cytoskeleton regulation in interleukin-13-induced minimal change-like nephropathy. <i>Clinical Science</i> , 2016, 130, 2317-2327.	1.8	8
93	Risk factors associated with the development of histocompatibility leukocyte antigen sensitization. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 447-452.	0.8	4
94	T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1360-1368.	2.2	23
95	Potential Roles for C1 Inhibitor in Transplantation. <i>Transplantation</i> , 2016, 100, 1415-1424.	0.5	39
96	Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. <i>New England Journal of Medicine</i> , 2016, 374, 940-950.	13.9	279
97	Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 6-8.	3.0	6
98	A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. <i>Transplantation</i> , 2015, 99, 2356-2363.	0.5	159
99	<sc>polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab. <i>Transplant Infectious Disease</i> , 2015, 17, 838-847.	0.7	13
100	Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. <i>Transplantation</i> , 2015, 99, 1423-1430.	0.5	61
101	Genetic Interactions Between TRPC6 and NPHS1 Variants Affect Posttransplant Risk of Recurrent Focal Segmental Glomerulosclerosis. <i>American Journal of Transplantation</i> , 2015, 15, 3229-3238.	2.6	17
102	Combined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database. <i>American Surgeon</i> , 2015, 81, 1047-1052.	0.4	16
103	Kidney transplantation in highly sensitized patients. <i>British Medical Bulletin</i> , 2015, 114, 113-125.	2.7	63
104	Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection. <i>Transplant Immunology</i> , 2015, 32, 9-17.	0.6	24
105	A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients. <i>Transplantation</i> , 2015, 99, 299-308.	0.5	128
106	Achieving incompatible transplantation through desensitization: current perspectives and future directions. <i>Immunotherapy</i> , 2015, 7, 377-398.	1.0	22
107	Modern approaches to incompatible kidney transplantation. <i>World Journal of Nephrology</i> , 2015, 4, 354.	0.8	25
108	Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process. <i>Clinical Transplants</i> , 2015, 31, 163-172.	0.2	0



#	ARTICLE	IF	CITATIONS
109	Immunologic and Infectious Complications in Highly Sensitized Patients Post-Kidney Transplantation. <i>Clinical Transplants</i> , 2015, 31, 265-273.	0.2	1
110	Transplantation in highly HLA-sensitized patients: challenges and solutions. <i>Transplant Research and Risk Management</i> , 2014, , 99.	0.7	1
111	Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. <i>Clinical Transplantation</i> , 2014, 28, 546-553.	0.8	31
112	Anti-Interleukin 6 Receptor Antibodies Attenuate Antibody Recall Responses in a Mouse Model of Allosensitization. <i>Transplantation</i> , 2014, 98, 1262-1270.	0.5	59
113	Donor-specific antibodies in allograft recipients. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 591-597.	0.8	41
114	Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients. <i>Transplantation</i> , 2014, 98, 312-319.	0.5	111
115	Regulation of Anti-HLA Antibody-Dependent Natural Killer Cell Activation by Immunosuppressive Agents. <i>Transplantation</i> , 2014, 97, 294-300.	0.5	31
116	Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy. <i>Clinical and Experimental Immunology</i> , 2014, 178, 48-51.	1.1	8
117	The Authors' Reply. <i>Transplantation</i> , 2014, 98, e8-e9.	0.5	0
118	7 <sup>th</sup> International Immunoglobulin Conference: Foreword. <i>Clinical and Experimental Immunology</i> , 2014, 178, 1-2.	1.1	10
119	7 <sup>th</sup> International Immunoglobulin Conference: Transplantation. <i>Clinical and Experimental Immunology</i> , 2014, 178, 46-47.	1.1	1
120	7 <sup>th</sup> International Immunoglobulin Conference: Transplantation. <i>Clinical and Experimental Immunology</i> , 2014, 178, 64-64.	1.1	2
121	Immunoglobulins: current understanding and future directions. <i>Clinical and Experimental Immunology</i> , 2014, 178, 163-168.	1.1	13
122	Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter Study. <i>American Journal of Transplantation</i> , 2014, 14, 1573-1580.	2.6	157
123	Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab. <i>Transplantation</i> , 2014, 97, 755-761.	0.5	26
124	Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. <i>Transplant Immunology</i> , 2013, 28, 138-143.	0.6	41
125	Donor-specific HLA antibodies and renal allograft failure. <i>Nature Reviews Nephrology</i> , 2013, 9, 130-131.	4.1	30
126	Defining the Benefits of Desensitization Therapy. <i>Transplantation</i> , 2013, 95, e31-e32.	0.5	5



#	ARTICLE	IF	CITATIONS
127	Efficacy, Outcomes, and Cost-Effectiveness of Desensitization Using IVIG and Rituximab. Transplantation, 2013, 95, 852-858.	0.5	99
128	Anti-CD3 $\mu$ induces splenic B220 lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization. International Immunology, 2012, 24, 529-538.	1.8	4
129	Significant Reduction of ATP Production in PHA-Activated CD4+ Cells in 1-Day-Old Blood from Transplant Patients. Transplantation, 2012, 94, 1243-1249.	0.5	10
130	Advancing kidney transplantation. Expert Review of Clinical Immunology, 2012, 8, 591-593.	1.3	0
131	The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nature Reviews Nephrology, 2012, 8, 348-357.	4.1	321
132	IFN $\gamma$ production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transplant Immunology, 2012, 26, 107-112.	0.6	24
133	Complement fixing donor $\alpha$ -specific antibodies and allograft loss. Pediatric Transplantation, 2012, 16, 1-3.	0.5	3
134	Desensitization Offers Hope to Highly HLA-Sensitized Patients for a Longer Life Expectancy After Incompatible Kidney Transplant. American Journal of Kidney Diseases, 2012, 59, 758-760.	2.1	8
135	Desensitizing the Broadly Human Leukocyte Antigen $\alpha$ -Sensitized Patient Awaiting Deceased Donor Kidney Transplantation. Transplantation Proceedings, 2012, 44, 60-61.	0.3	10
136	Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discovery Medicine, 2012, 13, 235-45.	0.5	13
137	Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discovery Medicine, 2012, 13, 267-73.	0.5	14
138	Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transplant Immunology, 2011, 24, 142-148.	0.6	16
139	B-cell immunotherapeutics. Current Opinion in Organ Transplantation, 2011, 16, 416-424.	0.8	37
140	Antibody Testing Strategies for Deceased Donor Kidney Transplantation After Immunomodulatory Therapy. Transplantation, 2011, 92, 48-53.	0.5	29
141	Clinical Aspects of Intravenous Immunoglobulin Use in Solid Organ Transplant Recipients. American Journal of Transplantation, 2011, 11, 196-202.	2.6	153
142	Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clinical and Experimental Nephrology, 2011, 15, 164-170.	0.7	18
143	Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Review of Clinical Immunology, 2011, 7, 341-348.	1.3	52
144	Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2894-2900.	2.2	82

#	ARTICLE	IF	CITATIONS
145	Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients. <i>Transplantation</i> , 2010, 90, 1473-1477.	0.5	180
146	Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation. <i>Transplantation</i> , 2010, 89, 1095-1102.	0.5	213
147	Advances in diagnosing and managing antibody-mediated rejection. <i>Pediatric Nephrology</i> , 2010, 25, 2035-2048.	0.9	68
148	Is Rituximab Safe to Use in Kidney Transplant Patients?. <i>American Journal of Transplantation</i> , 2010, 10, 8-9.	2.6	10
149	<i>Transplant Immunology</i> , 2010, , 356-363.		0
150	Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2207-2212.	2.2	177
151	Intracellular IFN $\gamma$ production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization. <i>Transplant Immunology</i> , 2010, 22, 121-127.	0.6	10
152	Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. <i>Transplant Immunology</i> , 2010, 23, 117-120.	0.6	8
153	Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. <i>Transplant Immunology</i> , 2010, 23, 133-140.	0.6	7
154	In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. <i>Transplant Immunology</i> , 2010, 23, 170-173.	0.6	5
155	Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1993-1997.	2.2	113
156	Modelling the response of a standing person to the slipstream generated by a passenger train. <i>Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit</i> , 2009, 223, 567-579.	1.3	13
157	Therapeutic plasma exchange for desensitization prior to transplantation in ABO $\alpha$ incompatible renal allografts. <i>Journal of Clinical Apheresis</i> , 2009, 24, 155-160.	0.7	25
158	Intravenous immunoglobulin as treatment for BK virus: Nephropathy. <i>Pediatric Transplantation</i> , 2009, 13, 11-13.	0.5	13
159	Intravenous Immunoglobulin a Natural Regulator of Immunity and Inflammation. <i>Transplantation</i> , 2009, 88, 1-6.	0.5	102
160	Design Considerations for Micro- and Nanopositioning: Leveraging the Latest for Biophysical Applications. <i>Current Pharmaceutical Biotechnology</i> , 2009, 10, 515-521.	0.9	8
161	Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab. <i>American Journal of Transplantation</i> , 2008, 8, 144-149.	2.6	57
162	Outcome of management strategies for BK virus replication in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2008, 12, 180-186.	0.5	22

#	ARTICLE	IF	CITATIONS
163	Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. <i>Pediatric Transplantation</i> , 2008, 12, 778-784.	0.5	29
164	Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization. <i>Transplant Immunology</i> , 2008, 19, 178-186.	0.6	11
165	Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation. <i>New England Journal of Medicine</i> , 2008, 359, 242-251.	13.9	624
166	A study of the slipstreams of high-speed passenger trains and freight trains. <i>Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit</i> , 2008, 222, 177-193.	1.3	94
167	Therapeutic Strategies in Management of the Highly HLA-Sensitized and ABO-Incompatible Transplant Recipients. <i>Contributions To Nephrology</i> , 2008, 162, 13-26.	1.1	38
168	Acceptable Donor-Specific Antibody Levels Allowing for Successful Deceased and Living Donor Kidney Transplantation After Desensitization Therapy. <i>Transplantation</i> , 2008, 86, 820-825.	0.5	122
169	Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 377-380.	0.4	36
170	Overexpression of Interleukin-13 Induces Minimal-Change-Like Nephropathy in Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1476-1485.	3.0	192
171	Desensitization protocols for crossing human leukocyte antigen and ABO incompatible barriers. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 371-378.	0.8	4
172	14th International HLA and Immunogenetics Workshop: Report on understanding antibodies in transplantation. <i>Tissue Antigens</i> , 2007, 69, 160-173.	1.0	33
173	The onset of rapidly progressive neurologic deterioration after a brief gastrointestinal illness in a renal allograft recipient. <i>Transplant Infectious Disease</i> , 2007, 9, 142-147.	0.7	7
174	Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. <i>Rheumatology International</i> , 2007, 27, 655-660.	1.5	9
175	Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. <i>Pediatric Nephrology</i> , 2007, 22, 2059-2065.	0.9	65
176	Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 844-852.	2.2	71
177	Adenovirus mediated IL-10 gene transfer to the airway of the rat lung for prevention of lung allograft rejection. <i>Transplant Immunology</i> , 2006, 16, 95-98.	0.6	18
178	Transplantation of the highly human leukocyte antigen-sensitized patient: long-term outcomes and future directions. <i>Transplantation Reviews</i> , 2006, 20, 146-156.	1.2	14
179	344 OVEREXPRESSION OF INTERLEUKIN-13 INDUCES MINIMAL CHANGE-LIKE NEPHROPATHY IN RATS AND IS ASSOCIATED WITH INCREASED B7-1 EXPRESSION IN THE GLOMERULI.. <i>Journal of Investigative Medicine</i> , 2006, 54, S139.3-S139.	0.7	1
180	Isolated heart and liver transplant recipients are at low risk for polyomavirus BKV nephropathy. <i>Clinical Transplantation</i> , 2006, 20, 289-294.	0.8	27

#	ARTICLE	IF	CITATIONS
181	Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. <i>American Journal of Transplantation</i> , 2006, 6, 459-466.	2.6	148
182	Effect of Induction Therapy Protocols on Transplant Outcomes in Crossmatch Positive Renal Allograft Recipients Desensitized with IVIG. <i>American Journal of Transplantation</i> , 2006, 6, 2384-2390.	2.6	53
183	Presensitization: The Problem and Its Management. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 421-432.	2.2	104
184	Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. <i>Transactions of the American Clinical and Climatological Association</i> , 2006, 117, 199-211; discussion 211.	0.9	29
185	Co-infection of Polyomavirus-BK and Cytomegalovirus in Renal Transplant Recipients. <i>Transplantation</i> , 2005, 80, 198-205.	0.5	63
186	Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection. <i>Pediatric Transplantation</i> , 2005, 9, 155-161.	0.5	43
187	Current approaches to treatment of antibody-mediated rejection. <i>Pediatric Transplantation</i> , 2005, 9, 408-415.	0.5	93
188	Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. <i>Transplant Infectious Disease</i> , 2005, 7, 71-74.	0.7	75
189	Cellular Immune Responses to Cytomegalovirus in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 110-117.	2.6	86
190	Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. <i>Pediatric Nephrology</i> , 2005, 20, 1376-1381.	0.9	61
191	Cyclosporine-sparing effects of daclizumab in renal allograft recipients. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 391-396.	0.5	5
192	Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 3256-3262.	3.0	397
193	Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. <i>Pediatric Nephrology</i> , 2004, 19, 627-632.	0.9	72
194	Consensus Opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-Mediated Rejection and Desensitization Protocols. <i>Transplantation</i> , 2004, 78, 181-185.	0.5	90
195	Immunomodulatory Effects of Combination of Pooled Human Gammaglobulin and Rapamycin on Cell Proliferation and Apoptosis in the Mixed Lymphocyte Reaction. <i>Transplantation</i> , 2004, 78, 1134-1138.	0.5	15
196	Pooled Human Gammaglobulin Modulates Surface Molecule Expression and Induces Apoptosis in Human B Cells. <i>American Journal of Transplantation</i> , 2003, 3, 156-166.	2.6	78
197	Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost Implications. <i>American Journal of Transplantation</i> , 2003, 3, 653-664.	2.6	126
198	Fabry Disease in a Renal Allograft. <i>American Journal of Transplantation</i> , 2003, 3, 1030-1032.	2.6	13

#	ARTICLE	IF	CITATIONS
199	Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1114-1120.	2.1	121
200	Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor- $\alpha$ production. <i>Clinical and Experimental Immunology</i> , 2003, 134, 111-119.	1.1	14
201	Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients <sup>1</sup> . <i>Transplantation</i> , 2003, 76, 631-636.	0.5	219
202	Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation <sup>1</sup> . <i>Transplantation</i> , 2003, 76, 348-353.	0.5	93
203	Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. <i>Clinical Transplants</i> , 2003, , 193-8.	0.2	5
204	IMPACT OF HEPATITIS B CORE ANTIBODY STATUS ON OUTCOMES OF CADAVERIC RENAL TRANSPLANTATION. <i>Transplantation</i> , 2002, 73, 85-89.	0.5	53
205	Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation. <i>Transplantation</i> , 2002, 74, 1648-1651.	0.5	4
206	Transient cold preservation alone stimulates tumor necrosis factor- $\alpha$ gene expression in a model of rat syngeneic lung transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 1111-1113.	0.3	0
207	Treatment of Parvovirus B-19 (PV B-19) Infection Allows for Successful Kidney Transplantation Without Disease Recurrence. <i>American Journal of Transplantation</i> , 2002, 2, 425-428.	2.6	36
208	Treatment of Active Cytomegalovirus Disease with Oral Ganciclovir in Renal Allograft Recipients: Monitoring Efficacy with Quantitative Cytomegalovirus Polymerase Chain Reaction. <i>American Journal of Transplantation</i> , 2002, 2, 671-673.	2.6	6
209	Management of the Highly HLA- Sensitized Patient. A Novel Role for Intravenous Gammaglobulin. <i>American Journal of Transplantation</i> , 2002, 2, 691-692.	2.6	27
210	Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, $\beta$ -IFN and IL-4) in vitro. <i>Transplant Immunology</i> , 2001, 9, 1-6.	0.6	10
211	CYCLOSPORINE MICROEMULSION??? AND MYCOPHENOLATE MOFETIL???RELATED LYMPHOID AGGREGATES ARE NOT ASSOCIATED WITH ACUTE REJECTION. <i>Transplantation</i> , 2001, 72, 251-256.	0.5	5
212	PROLONGATION OF ALLOGRAFT SURVIVAL WITH VIRAL IL-10 TRANSFECTION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT HEART ALLOGRAFT REJECTION <sup>1</sup> . <i>Transplantation</i> , 2001, 71, 686-691.	0.5	46
213	Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. <i>Kidney International</i> , 2001, 59, 2126-2133.	2.6	186
214	Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. <i>Kidney International</i> , 2001, 59, 2126.	2.6	24
215	HYDROPHOBIC EXTRACTS OF A CHINESE HERB (CMX-13) EXHIBIT POTENT IMMUNOSUPPRESSIVE PROPERTIES AND PREVENT ACUTE REJECTION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT LUNG TRANSPLANTATION <sup>1</sup> . <i>Transplantation</i> , 2000, 70, 1094-1098.	0.5	2
216	Improvement in Lupus Nephritis Following Treatment With a Chinese Herbal Preparation. <i>JAMA Pediatrics</i> , 1999, 153, 850.	3.6	5

#	ARTICLE	IF	CITATIONS
217	Expression of $\hat{I}^c$ -IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. <i>Clinical Transplantation</i> , 1999, 13, 201-207.	0.8	42
218	Renal transplantation in infants and children. <i>Indian Journal of Pediatrics</i> , 1999, 66, 263-275.	0.3	0
219	Lung allograft dysfunction correlates with $\hat{I}^3$ -interferon gene expression in bronchoalveolar lavage. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 627-636.	0.3	54
220	Antithrombin III inhibits T- and B-lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. <i>Transplantation Proceedings</i> , 1999, 31, 816-817.	0.3	6
221	Decreased $\hat{I}^3$ -IFN and IL-2 gene expression in regional lymph nodes of skin allografts is associated with increased allograft survival in the WKY F344 rat model. <i>Transplantation Proceedings</i> , 1999, 31, 818-819.	0.3	0
222	Antithrombin III inhibits T and B lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. <i>Transplantation Proceedings</i> , 1999, 31, 847-848.	0.3	9
223	THE CLINICAL SIGNIFICANCE OF ANTIBODIES TO HUMAN VASCULAR ENDOTHELIAL CELLS AFTER CARDIAC TRANSPLANTATION <sup>1</sup> . <i>Transplantation</i> , 1999, 67, 385-391.	0.5	101
224	ANTITHROMBIN III TREATMENT IMPROVES PARAMETERS OF ACUTE INFLAMMATION IN A HIGHLY HISTOINCOMPATIBLE MODEL OF RAT LUNG ALLOGRAFT REJECTION. <i>Transplantation</i> , 1999, 67, 526-528.	0.5	18
225	POOLED HUMAN GAMMAGLOBULIN (IVIG) INHIBITS THE MIXED LYMPHOCYTE REACTION (MLR) THROUGH MODULATION OF SURFACE MOLECULES ON ANTIGEN PRESENTING CELLS (APC). <i>Transplantation</i> , 1999, 67, S59.	0.5	1
226	Dacluzimab is Comparable to Antithymocyte Globulin (ATG) Induction in Preventing Acute Rejection (AR) Episodes in High Risk Renal Transplant Recipients. <i>Transplantation</i> , 1999, 67, S151.	0.5	1
227	IMMUNOLOGICAL CHARACTERIZATION OF ANTI-ENDOTHELIAL CELL ANTIBODIES INDUCED BY CYTOMEGALOVIRUS INFECTION <sup>1</sup> . <i>Transplantation</i> , 1999, 68, 1311-1318.	0.5	41
228	PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IS ASSOCIATED WITH REDUCED Th1 CYTOKINE RESPONSES IN THE WKY F344 RAT MODEL. <i>Transplantation</i> , 1999, 68, 1393-1401.	0.5	16
229	PRELIMINARY RESULTS FROM A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL OF INTRAVENOUS GAMMAGLOBULIN (IVIG) + PULSE STEROIDS (PS) FOR THE TREATMENT OF ACUTE REJECTION (AR) EPISODES IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1999, 67, S117.	0.5	0
230	Nephronophthisis associated with Ellis-van Creveld syndrome. <i>Pediatric Nephrology</i> , 1998, 12, 20-22.	0.9	35
231	Pre-transplant donor-specific transfusions induce allograft rejection and IL-2 gene expression in the WKY $\hat{I}^c$ F344 functional tolerance model of rat lung transplantation. <i>Transplant Immunology</i> , 1998, 6, 137-146.	0.6	11
232	Immunosuppressive Effect of the Hydrophobic Extract of a Chinese Herb on Rat Lung Allograft Rejection. <i>Transplantation Proceedings</i> , 1998, 30, 980-981.	0.3	5
233	TOLERANCE INDUCTION BY INTRATHYMIC INOCULATION PREVENTS CHRONIC RENAL ALLOGRAFT REJECTION <sup>1,2</sup> . <i>Transplantation</i> , 1998, 65, 272-275.	0.5	11
234	POSTTRANSPLANT THERAPY USING HIGH-DOSE HUMAN IMMUNOGLOBULIN (INTRAVENOUS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 RECIPIENTS AND POTENTIAL MECHANISM OF ACTION <sup>1</sup> . <i>Transplantation</i> , 1998, 66, 800-805.	0.5	238



#	ARTICLE	IF	CITATIONS
235	A STABLE PROSTACYCLIN ANALOG, BERAPROST SODIUM, ATTENUATES PLATELET ACCUMULATION AND PRESERVATION-REPERFUSION INJURY OF ISOGRAFTS IN A RAT MODEL OF LUNG TRANSPLANTATION <sup>1</sup> . <i>Transplantation</i> , 1998, 66, 1132-1136.	0.5	18
236	PREVENTION AND PREEMPTIVE THERAPY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 1998, 66, 1604-1611.	0.5	314
237	Immunomodulatory actions of intravenous immunoglobulin (IVIg): potential applications in solid organ transplant recipients. <i>Pediatric Transplantation</i> , 1998, 2, 92-105.	0.5	26
238	Selective expression of the interleukin-2 gene discriminates between the auto- and allo-mixed lymphocyte reaction. <i>Transplant Immunology</i> , 1997, 5, 35-38.	0.6	9
239	Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. <i>Transplant Immunology</i> , 1997, 5, 104-111.	0.6	68
240	CORRELATION OF CYTOMEGALOVIRUS DNA LEVELS WITH RESPONSE TO ANTIVIRAL THERAPY IN CARDIAC AND RENAL ALLOGRAFT RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 1997, 63, 957-963.	0.5	54
241	ACCUMULATION OF PLATELETS IN RAT SYNGENEIC LUNG TRANSPLANTS. <i>Transplantation</i> , 1997, 64, 801-806.	0.5	54
242	URETERITIS AND CHOLECYSTITIS. <i>Transplantation</i> , 1997, 64, 1071-1073.	0.5	31
243	LONG-TERM ALLOGRAFT ACCEPTANCE IN A PATIENT WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. <i>Transplantation</i> , 1997, 64, 1578-1582.	0.5	16
244	PARVOVIRUS B19 INFECTION-RELATED COMPLICATIONS IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 64, 1847-1850.	0.5	119
245	Induction of specific tolerance through mixed hematopoietic chimerism prevents chronic renal allograft rejection in a rat model. <i>Surgery</i> , 1996, 120, 213-220.	1.0	21
246	Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporine A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection. <i>Transplant Immunology</i> , 1996, 4, 33-37.	0.6	9
247	Delayed Development of Obliterative Bronchiolitis Syndrome With OKT3 After Unilateral Lung Transplantation. <i>Chest</i> , 1996, 109, 870-873.	0.4	31
248	SOLUBLE CTLA4Ig MODIFIES PARAMETERS OF ACUTE INFLAMMATION IN RAT LUNG ALLOGRAFT REJECTION WITHOUT ALTERING LYMPHOCYTIC INFILTRATION OR TRANSCRIPTION OF KEY CYTOKINES <sup>1</sup> . <i>Transplantation</i> , 1995, 59, 551-558.	0.5	26
249	ASSESSMENT OF PATHOLOGICAL CHANGES ASSOCIATED WITH CHRONIC ALLOGRAFT REJECTION AND TOLERANCE IN TWO EXPERIMENTAL MODELS OF RAT LUNG TRANSPLANTATION. <i>Transplantation</i> , 1995, 59, 1509-1516.	0.5	57
250	Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. <i>Journal of Clinical Immunology</i> , 1995, 15, S76-S85.	2.0	18
251	Modification of the Senning repair in a case of transposition of the great arteries with juxtaposition of the atrial appendages. <i>European Journal of Cardio-thoracic Surgery</i> , 1995, 9, 50-51.	0.6	5
252	Treatment of Stevens-Johnson Syndrome With Pooled Human Intravenous Immune Globulin. <i>Clinical Pediatrics</i> , 1995, 34, 48-51.	0.4	23



#	ARTICLE	IF	CITATIONS
253	Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. <i>Transplant Immunology</i> , 1995, 3, 151-161.	0.6	47
254	Alterations of the interleukin-4 pathway in production of tolerance by mixed hematopoietic chimerism*. <i>Surgery</i> , 1995, 118, 212-219.	1.0	7
255	Prevention Of Chronic Rejection And Graft Arteriosclerosis By Tolerance Induction. <i>Transplantation</i> , 1995, 59, 282-287.	0.5	64
256	Prevention Of Chronic Rejection And Graft Arteriosclerosis By Tolerance Induction. <i>Transplantation</i> , 1995, 59, 282-287.	0.5	3
257	Use of polymerase chain reaction to rapidly detect cytomegalovirus DNA in peripheral blood leukocytes of transplant recipients. <i>Transplantation Proceedings</i> , 1995, 27, 1272-3.	0.3	6
258	Soluble CTLA4Ig modifies acute rejection of rat lung allografts without blocking accumulation of key cytokine transcripts. <i>Transplantation Proceedings</i> , 1995, 27, 406-8.	0.3	5
259	Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. <i>Journal of Clinical Immunology</i> , 1994, 14, 178-189.	2.0	67
260	Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. <i>Transplant Immunology</i> , 1994, 2, 337-341.	0.6	42
261	INTRAVENOUS IMMUNOGLOBULIN SUPPRESSION OF HLA ALLOANTIBODY IN HIGHLY SENSITIZED TRANSPLANT CANDIDATES AND TRANSPLANTATION WITH A HISTOINCOMPATIBLE ORGAN. <i>Transplantation</i> , 1994, 57, 553-562.	0.5	220
262	GAMMA-INTERFERON GENE EXPRESSION IN HUMAN RENAL ALLOGRAFT FINE-NEEDLE ASPIRATES. <i>Transplantation</i> , 1994, 57, 498-501.	0.5	11
263	GAMMA-INTERFERON GENE EXPRESSION IN HUMAN RENAL ALLOGRAFT FINE-NEEDLE ASPIRATES. <i>Transplantation</i> , 1994, 57, 498-501.	0.5	45
264	Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. <i>Clinical and Experimental Immunology</i> , 1994, 97 Suppl 1, 31-8.	1.1	6
265	Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. <i>Transplantation</i> , 1994, 57, 553-62.	0.5	45
266	Successful balloon dilatation of ascending vein stenosis in obstructed supracardiac total anomalous pulmonary venous connection. <i>Pediatric Cardiology</i> , 1994, 15, 78-80.	0.6	21
267	Modulation of MHC Expression on Human Endothelial Cells by Sera from Patients with Systemic Lupus Erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1993, 68, 321-326.	2.1	8
268	Immunocytologic Analysis of Cells Obtained from Bronchoalveolar Lavage in a Model of Rat Lung Allograft Rejection. <i>Journal of Surgical Research</i> , 1993, 55, 351-356.	0.8	17
269	THE PARTICIPATION OF TUMOR NECROSIS FACTOR IN THE PATHOGENESIS OF LUNG ALLOGRAFT REJECTION IN THE RAT. <i>Transplantation</i> , 1993, 55, 967-971.	0.5	30
270	Immunosuppression in organ transplantation. <i>Seminars in Pediatric Surgery</i> , 1993, 2, 206-7.	0.5	4

#	ARTICLE	IF	CITATIONS
271	Treatment of Antineutrophil Cytoplasmic Autoantibody-Positive Systemic Vasculitis and Glomerulonephritis With Pooled Intravenous Gammaglobulin. <i>American Journal of Kidney Diseases</i> , 1992, 20, 504-508.	2.1	47
272	Vascular rejection and graft eosinophilia in rat lung allografts. <i>Journal of Surgical Research</i> , 1991, 51, 310-315.	0.8	13
273	Cell-Mediated Immunity in Patients on Hemodialysis: Relationship with Hepatitis B Carrier Status. <i>American Journal of Nephrology</i> , 1991, 11, 98-101.	1.4	10
274	STIMULUS-SPECIFIC 1,25(OH) <sub>2</sub> D <sub>3</sub> MODULATION OF TNF AND IL-1-BETA GENE EXPRESSION IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS AND MONOCYTOID CELL LINES. <i>Transplantation</i> , 1991, 51, 498-502.	0.5	18
275	Inhibition of Protein-Kinase C in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus: Effect on Spontaneous Immunoglobulin Production. <i>Autoimmunity</i> , 1991, 10, 227-231.	1.2	2
276	Cytokine gene activation in rat lung allografts: analysis by northern blotting. <i>Transplantation Proceedings</i> , 1991, 23, 604-6.	0.3	10
277	Metabolic and Hematologic Effects and Immune Complex Formation Related to Pertussis Immunization. <i>Pediatric Research</i> , 1990, 27, 353-357.	1.1	15
278	Anti-vascular endothelial cell antibodies in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 1990, 162, 138-146.	0.7	100
279	A new percutaneous renal biopsy device for pediatric patients. <i>Pediatric Nephrology</i> , 1989, 3, 191-193.	0.9	17
280	1,25 Dihydroxyvitamin-D <sub>3</sub> regulation of immunoglobulin production in peripheral blood mononuclear cells of patients with Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 1989, 2, 861-867.	3.0	10
281	Intravenous $\hat{I}^3$ -globulin therapy in systemic lupus erythematosus and immune complex disease. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, S164-S169.	2.1	69
282	1-Oleoyl-2-acetyl-glycerol promotes immunoglobulin production independent of cell proliferation in human peripheral blood mononuclear cells. <i>Biochemical and Biophysical Research Communications</i> , 1989, 161, 1319-1326.	1.0	1
283	Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: Relationship to clinical activity. <i>Clinical Immunology and Immunopathology</i> , 1988, 47, 354-362.	2.1	38
284	Anti-vascular endothelial cell antibodies in patients with IgA nephropathy: Frequency and clinical significance. <i>Clinical Immunology and Immunopathology</i> , 1988, 49, 450-462.	2.1	39
285	HYPERACUTE ALLOGRAFT REJECTION MEDIATED BY ANTI-VASCULAR ENDOTHELIAL CELL ANTIBODIES WITH A NEGATIVE MONOCYTE CROSSMATCH. <i>Transplantation</i> , 1988, 46, 585-586.	0.5	46
286	DETERMINATION OF ANTIIDIOTYPIC ANTIBODIES TO ANTI-HLA IgG FOLLOWING BLOOD TRANSFUSIONS. <i>Transplantation</i> , 1987, 44, 30-33.	0.5	19
287	Detection of bovine serum albumin in the circulating IgA immune complexes of patients with IgA nephropathy. <i>Clinical Immunology and Immunopathology</i> , 1987, 43, 395-402.	2.1	24
288	Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. <i>Pediatric Nephrology</i> , 1987, 1, 276-280.	0.9	22

#	ARTICLE	IF	CITATIONS
289	Experience With Renal Transplantation in Children Undergoing Peritoneal Dialysis (CAPD/CCPD). American Journal of Kidney Diseases, 1986, 8, 181-185.	2.1	24
290	Petechiae and urticaria after DTP vaccination: Detection of circulating immune complexes containing vaccine-specific antigens. Journal of Pediatrics, 1986, 109, 1009-1012.	0.9	30
291	Postpartum Renal Failure in a Patient with Membranoproliferative Glomerulonephritis Type II. American Journal of Nephrology, 1986, 6, 382-385.	1.4	7
292	SPONTANEOUS ANTI-TUBULAR-BASEMENT-MEMBRANE ANTIBODY PRODUCTION BY LYMPHOCYTES ISOLATED FROM A REJECTED ALLOGRAFT. Transplantation, 1986, 41, 173-176.	0.5	12
293	SHORT-COURSE ANTITHYMOCYTE GLOBULIN FOR TREATMENT OF RENAL TRANSPLANT REJECTION IN CHILDREN. Transplantation, 1986, 41, 133-134.	0.5	4
294	Circulating immune complexes in Kawasaki syndrome. Pediatric Infectious Disease Journal, 1985, 4, 48-51.	1.1	45
295	Quantitation of circulating immune complexes in human serum by the Raji cell and F(ab $\epsilon$ ) <sub>2</sub> anti-C3 micro enzyme immunoassays. Journal of Immunological Methods, 1985, 83, 363-370.	0.6	15
296	Induction of neonatal renal tubular dysfunction by transplacentally acquired IgG from a mother with Sjögren syndrome. Journal of Pediatrics, 1985, 107, 566-569.	0.9	19
297	1,25-Dihydroxyvitamin D <sub>3</sub> suppresses human T helper/inducer lymphocyte activity in vitro. Journal of Immunology, 1985, 134, 3032-5.	0.4	200
298	Acute Bromate Poisoning Associated with Renal Failure and Deafness Presenting as Hemolytic Uremic Syndrome. American Journal of Nephrology, 1984, 4, 188-191.	1.4	26
299	1 alpha,25-dihydroxyvitamin D <sub>3</sub> suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells.. Journal of Clinical Investigation, 1984, 74, 657-661.	3.9	439
300	False-negative anti-DNA antibody activity in infantile systemic Lupus erythematosus (SLE). Journal of Clinical Immunology, 1984, 4, 156-162.	2.0	18
301	Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.. British Journal of Clinical Pharmacology, 1984, 18, 725-732.	1.1	8
302	Characterization of soluble circulating immune complexes by antigen-specific dissociation: Detection in the Raji cell radioimmune assay. Clinical Immunology and Immunopathology, 1983, 27, 357-368.	2.1	5
303	Continuous Ambulatory Peritoneal Dialysis Catheters in Children. Archives of Surgery, 1983, 118, 1398.	2.3	28
304	CADAVER RENAL TRANSPLANT OUTCOME IN RECIPIENTS WITH AUTOLYMPHOCYTOTOXIC ANTIBODIES. Transplantation, 1983, 35, 429-431.	0.5	30
305	Circulating Immune Complexes during Various Forms of Renal Allograft Rejection Episodes. Nephron, 1982, 31, 141-145.	0.9	0
306	Plasma inhibition of lymphocyte proliferation in nephrotic syndrome: Correlation with hyperlipidemia. Journal of Clinical Immunology, 1982, 2, 276-281.	2.0	17

#	ARTICLE	IF	CITATIONS
307	AUTOLYMPHOCYTOTOXIC ANTIBODIES IN PATIENTS ON DIALYSIS AWAITING RENAL TRANSPLANTATION. Transplantation, 1981, 32, 248-251.	0.5	11
308	941 PLASMA INHIBITION OF LYMPHOCYTE BLASTOGENESIS IN NEPHROTIC SYNDROME: CORRELATION WITH HYPERLIPIDEMIA. Pediatric Research, 1981, 15, 599-599.	1.1	0
309	CIRCULATING IMMUNE COMPLEXES IN PEDIATRIC RENAL ALLOGRAFT REJECTION. Transplantation, 1981, 31, 190-194.	0.5	9
310	Studies of Immune-Complex Glomerulonephritis Mediated by Human Thyroglobulin. New England Journal of Medicine, 1981, 304, 1212-1215.	13.9	87
311	Circulating Immune Complexes in Patients with Cystic Fibrosis. Chest, 1981, 80, 405-411.	0.4	26
312	DEMONSTRATION OF CIRCULATING IMMUNE COMPLEXES (CICs) CONTAINING HUMAN THYROGLOBULIN (HuTg) IN A PATIENT WITH IMMUNE COMPLEX GLOMERULONEPHRITIS (ICGN) MEDIATED BY THYROGLOBULIN ANTI-THYROGLOBULIN IMMUNE COMPLEXES. Pediatric Research, 1980, 14, 1013-1013.	1.1	0
313	ACCELERATED ACUTE REJECTION OF PRIMARY RENAL ALLOGRAFTS IN PEDIATRIC PATIENTS. Transplantation, 1980, 30, 5-8.	0.5	7
314	Hepatitis B infection in pediatric dialysis and transplant patients: Significance of e antigen. Journal of Pediatrics, 1980, 97, 550-553.	0.9	6
315	Chronic pericardial constriction with effusion in childhood.. Archives of Disease in Childhood, 1979, 54, 890-895.	1.0	8
316	Pancreatitis in children and adolescents. Journal of Pediatrics, 1977, 91, 211-216.	0.9	77
317	Rituximab: An emerging therapeutic agent for kidney transplantation. Transplant Research and Risk Management, 0, Volume 1, 15-29.	0.7	8
318	Therapies for the Allosensitized Patient. , 0, , 95-102.		0